Shanghai, China – October 12, 2026 – Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry’s development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, reimbursement pathways, and the competitive landscape. It also identifies key challenges and opportunities in vector technologies, large-scale manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks, while exploring the industry’s current landscape and future trends driven by technological breakthroughs, regulatory improvements, capital investment, and commercialization. By connecting industry participants, investment institutions, and regulatory authorities, the report provides forward-looking market insights and strategic guidance for technology planning, product development, industrialization, international collaboration, and the improvement of industry standards. (To read the 2026 Global Gene Therapy Industry Development Blue Book, visit: https://hub.frost.com/global-gene-therapy-industry-development/ )

Gene therapy is an innovative therapeutic approach that treats diseases by modifying, replacing, supplementing, or regulating human genes, targeting genetic abnormalities at the root cause of disease. Unlike conventional drugs that primarily alleviate symptoms or slow disease progression through long-term administration, gene therapy aims to provide one-time or long-lasting therapeutic benefits, offering new possibilities for treating inherited disorders, ophthalmic diseases, cancer, and chronic conditions. With continued advances in gene editing, delivery systems, manufacturing processes, and commercialization capabilities, the global gene therapy industry is transitioning from early-stage technological exploration toward large-scale application.

Key Market Observations from the Blue Book

1. Technological Revolution: Gene Therapy Shifts Disease Treatment from Symptom Management to Addressing Underlying Causes

Gene therapy is built around the principle of addressing the underlying causes of disease. Four core technological approaches have emerged: gene replacement, gene addition, gene expression alteration, and gene editing.

Four Core Technological Approaches: From Gene Replacement to Precision Gene Editing

Gene Replacement: When genetic mutations prevent the synthesis of normal proteins, gene replacement introduces a functional copy of the gene to restore normal protein expression and correct the underlying disease. This approach is primarily applicable to inherited disorders caused by monogenic defects.

Gene Supplementation: For diseases driven by multiple genetic and/or environmental factors, gene supplementation introduces exogenous therapeutic genes to confer new or enhanced functions on target cells, thereby intervening in disease progression. Rather than directly repairing the original defective genes, this approach improves specific pathological mechanisms by introducing additional functional genes.

Gene Expression Regulation: This approach regulates abnormal expression levels of endogenous genes. Transcriptional activation or RNA activation (RNAa) can be used to upregulate genes with insufficient expression, while RNA interference (RNAi) or antisense oligonucleotides (ASOs) can silence overexpressed genes or genes producing toxic proteins. Unlike gene editing, gene expression regulation does not alter the underlying DNA sequence but modulates protein production at the transcriptional or post-transcriptional level.

Gene Editing: Gene editing employs programmable molecular tools, such as CRISPR-Cas9/Cas12 systems, to modify the patient’s genome through site-specific insertion, deletion, or substitution of nucleotides or nucleotide sequences, as well as epigenetic regulation of specific genes. These modifications can correct pathogenic mutations or alter gene expression levels. By directly modifying disease-causing DNA sequences or regulating their expression, gene editing enables more precise treatment of genetic and chronic diseases. It is generally regarded as a therapeutic approach with the potential to deliver long-term benefits following a single treatment.

2. Industry Advancement: Scalable Manufacturing and Quality Control Become Critical to Commercialization

As gene therapy pipelines progressively advance into late-stage clinical development and commercial registration, industry competition is shifting from R&D capabilities toward manufacturing capacity and Chemistry, Manufacturing and Controls (CMC) capabilities.

Delivery vectors are essential tools for gene therapy, enabling the targeted delivery of DNA, RNA, gene-editing tools, and other therapeutic genetic materials into target cells. Based on their origins and characteristics, delivery systems are broadly classified into two categories: viral vectors and non-viral vectors.

Viral vectors leverage the natural ability of viruses to infect cells for gene delivery, generally offering high transduction efficiency and relatively durable gene expression. They remain the dominant technological route in gene therapy. Non-viral vectors, by contrast, deliver genetic materials through lipid-based materials, polymers, exosomes, or physical delivery methods, offering advantages such as lower immunogenicity, larger payload capacity, and greater manufacturing flexibility.

Gene therapy can be further divided into two major approaches: in vivo gene therapy and ex vivo gene therapy.

In vivo gene therapy directly delivers vectors carrying therapeutic genes, gene-editing tools, or regulatory elements into the patient’s body, enabling gene expression, regulation, or editing within target tissue cells. Common delivery systems include adeno-associated viruses (AAVs), adenoviruses, and lipid nanoparticles (LNPs). Administration routes include intravenous injection, intraocular injection, intrathecal injection, and local administration. This approach is primarily applicable to diseases involving the eye, liver, central nervous system, muscles, cardiovascular system, and hematologic system. Although the treatment process is relatively straightforward, it places considerable requirements on tissue targeting, immunogenicity, in vivo safety, and large-scale manufacturing capabilities.

Ex vivo gene therapy, by contrast, involves collecting cells from patients or donors, modifying or editing their genes outside the body using delivery methods such as lentiviral vectors, retroviral vectors, or electroporation, and then reinfusing the modified cells after expansion, quality testing, and formulation. This approach is primarily applicable to cell types that can be collected, expanded, and reinfused, such as hematopoietic stem cells and T cells. Representative applications include CAR-T cell therapy, hematopoietic stem cell gene therapy for β-thalassemia and sickle cell disease, and various ex vivo gene-editing therapies.

Compared with in vivo gene therapy, ex vivo therapy places relatively lower requirements on vector biodistribution and targeted tissue delivery and offers greater control over clinical procedures. However, its manufacturing process is more complex, involving multiple steps such as cell collection, gene modification, expansion, release testing, and reinfusion, which place higher demands on manufacturing facilities, quality management systems, and personalized manufacturing capabilities. Together, in vivo and ex vivo gene therapy constitute the core framework for the clinical translation and industrialization of gene therapy.

Over the past several decades, gene therapy has evolved from early proof-of-concept research toward clinical translation and commercialization. Its therapeutic modalities have expanded beyond traditional gene replacement and gene supplementation to encompass CAR-T cell therapy, RNA interference (RNAi), oncolytic viruses, gene editing, and mRNA delivery. Continued advances in key technologies such as AAV, LNP, and CRISPR are expanding the range of treatable diseases, improving clinical development efficiency, and enhancing the potential for industrialization.

Looking across the industry’s development, viral vectors are expected to retain a dominant position in gene therapy delivery systems in the near term, supported by their high delivery efficiency and established clinical applications. Non-viral vectors are likely to become an increasingly important complementary approach, benefiting from larger payload capacity, lower immunogenicity, and more flexible manufacturing processes. As delivery systems, gene-editing tools, and manufacturing technologies continue to improve, in vivo and ex vivo gene therapies are expected to follow increasingly differentiated development pathways, collectively advancing the industry from individual technological breakthroughs toward multi-platform integration and large-scale commercialization.

Host cell lines represent only the starting point of the manufacturing process. Upstream process development also involves cell expansion, medium screening, optimization of transfection or infection conditions, and control of critical parameters such as cell density, viability, plasmid quality, and expression windows. Due to the relatively low volumetric yield of AAV and its reliance on complex intracellular biological mechanisms, manufacturing scale-up frequently encounters challenges involving viral titer, empty capsid ratios, and batch-to-batch consistency. These issues remain major bottlenecks affecting production costs and commercialization efficiency.

Downstream processing focuses on isolating intact viral particles containing the target gene from complex cell lysates. The process typically involves clarification, chromatographic purification, ultrafiltration/diafiltration, virus-removal filtration, and aseptic filling. A key challenge is removing host cell proteins, residual host cell DNA, empty capsids, and partially packaged particles while preserving intact capsids with transduction activity. For Sf9-based manufacturing systems, additional attention must be given to the removal of baculovirus-related and insect cell-derived impurities.

Consequently, competition in gene therapy manufacturing has evolved beyond host cell line selection to encompass integrated capabilities in cell culture, vector assembly, purification, quality control, and manufacturing scale-up. Companies with efficient host cell platforms, robust upstream and downstream processes, and commercial-scale manufacturing capabilities are expected to gain a competitive advantage.

3. Commercialization Prospects: From High-Value Patient Populations to Broader Chronic Disease Markets

The core value of gene therapy lies in its potential to transform disease treatment from continuous drug administration toward one-time intervention with long-term or potentially lifelong benefits.

However, successful commercialization depends not only on technological advancement but also on achieving an appropriate balance between clinical benefits and economic value. In general, diseases associated with a high disease burden, substantial unmet medical needs, and high long-term treatment costs are more likely to offer initial commercialization opportunities.

Major Therapeutic Areas Show a Phased Expansion Pattern

Currently, hemophilia, inherited eye diseases, and certain rare diseases present relatively well-defined patient populations, high disease burdens, and a need for long-term medication or repeated treatment. These characteristics make it easier to demonstrate the clinical and economic value of gene therapy through the potential for one-time treatment and sustained benefits.

As delivery technologies, manufacturing processes, and long-term follow-up data continue to improve, thalassemia, oncology, and central nervous system disorders are expected to emerge as additional growth areas.

Over the longer term, the commercialization potential of gene therapy will depend on establishing sufficient evidence of long-term safety, durability of efficacy, and treatment cost-effectiveness. If these requirements can be progressively met, chronic diseases such as diabetes and cardiovascular disorders could create substantially larger market opportunities.

Accordingly, the commercialization of gene therapy is expected to expand progressively from high-value, relatively small patient populations toward broader chronic disease populations.

Ophthalmology: Reducing the Burden of Repeated Treatment Through One-Time Intervention

A major challenge in the treatment of chronic ophthalmic diseases is the burden of frequent and prolonged drug administration. For retinal diseases such as neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), patients currently rely primarily on intravitreal anti-VEGF injections, often requiring follow-up visits or injections every four to eight weeks. Such prolonged treatment schedules may reduce patient adherence.

Ophthalmic gene therapy uses vectors such as AAV to deliver genes encoding anti-VEGF or anti-angiogenic proteins into retinal cells, enabling sustained expression of therapeutic proteins. Given the feasibility of localized intraocular administration, the relatively confined nature of ocular tissues, and clearly defined efficacy endpoints, ophthalmology has emerged as one of the therapeutic areas with considerable commercialization potential.

Its commercial value primarily lies in the possibility of substantially reducing injection frequency while maintaining visual function. If these benefits can be demonstrated, the value of a one-time gene therapy may be assessed against the cumulative costs of anti-VEGF drugs, injections, follow-up visits, and disease management over multiple years.

Inherited Hematologic Disorders: From Long-Term Transfusion Support to Potential Curative Treatment

Patients with transfusion-dependent β-thalassemia (TDT) typically require regular blood transfusions and iron chelation therapy over extended periods, facing risks such as iron overload and multi-organ damage. This creates a considerable long-term treatment burden.

Consequently, clinical management aims not only to control disease progression but also to achieve more durable therapeutic outcomes. By improving patients’ own hematopoietic function, gene therapy has the potential to help patients with TDT achieve long-term transfusion independence, offering a new treatment approach characterized by one-time intervention and sustained benefits.

From a commercialization perspective, gene therapy may reduce the long-term healthcare burden associated with repeated transfusions and iron chelation therapy. The economic value of a one-time treatment can therefore be assessed against the cumulative costs of conventional long-term care. As commercial health insurance and other supplementary insurance schemes continue to evolve, the long-term clinical and reimbursement value of gene therapy may be increasingly realized.

Central Nervous System Disorders: High-Value Opportunities Accompanied by Significant Validation Requirements

The primary challenges in treating central nervous system (CNS) disorders include the blood-brain barrier, which restricts drug delivery to the brain, and the often irreversible nature of neurological damage.

Gene therapy can bypass or overcome the blood-brain barrier through intrathecal administration, targeted intracerebral injection, or engineered AAV vectors, delivering therapeutic genes to the brain, spinal cord, or specific neural structures. This enables sustained gene expression in neurons or glial cells and may shift treatment from symptom management toward disease modification.

Spinal muscular atrophy (SMA), aromatic L-amino acid decarboxylase (AADC) deficiency, and certain neurodegenerative diseases have demonstrated substantial therapeutic value and potential for reimbursement. Nevertheless, the commercialization of CNS gene therapy remains highly dependent on evidence regarding delivery efficiency, long-term efficacy, neurotoxicity, and the invasiveness of administration procedures.

Oncology, Cardiovascular and Metabolic Diseases: Larger Patient Populations with Higher Commercialization Requirements

Gene therapy in oncology has entered a phase of clinical and reimbursement validation. Genetically engineered cell therapies such as CAR-T have already established high-value, one-time treatment models for hematologic malignancies. Further expansion into solid tumors will depend on target selection, safety management, and the capabilities of specialized treatment centers.

In cardiovascular and metabolic diseases, gene therapy is expected to initially focus on patients with inherited, refractory, or high-risk conditions. For example, in familial hypercholesterolemia, one-time or infrequent gene therapy interventions that achieve durable lipid control could potentially shift disease management from lifelong medication toward long-term risk modification.

However, compared with rare diseases and hematologic disorders, chronic diseases affect much larger patient populations, while existing treatments are often available at relatively manageable costs. Gene therapies targeting these conditions must therefore demonstrate more robust evidence of long-term safety, durability of efficacy, and cost-effectiveness.

Innovative Reimbursement Models Become Essential to Commercialization

The potential for one-time treatment with long-term benefits also presents significant challenges to conventional healthcare payment systems. The mismatch between high upfront treatment costs and benefits realized over extended periods has increased industry interest in innovative reimbursement mechanisms, including commercial health insurance, installment payments, and outcomes-based reimbursement.

Gene therapy products, which may offer long-term or potentially lifelong benefits following a single administration, challenge traditional payment systems structured around monthly or annual treatment expenditures. Developing diversified reimbursement mechanisms and expanding market access pathways will be essential to making gene therapies more affordable and accessible.

Currently, the industry is exploring various approaches, including public medical insurance, commercial health insurance, installment payments, and outcomes-linked reimbursement models. These mechanisms aim to reduce the immediate financial burden on patients and payers while improving access to high-value innovative therapies.

Over the longer term, the economic value of gene therapy is primarily based on the potential to replace continuous medication and disease management costs with one-time or infrequent treatment. A sustainable reimbursement model can only be established when products demonstrate durable efficacy, manageable safety risks, and long-term cost-effectiveness.

Global and Chinese Markets Enter an Accelerated Growth Phase

The global gene therapy market is transitioning from early commercialization toward large-scale application. According to the Blue Book, the global gene therapy therapeutics market is projected to grow from USD 0.1 billion in 2021 to USD 32.0 billion by 2035.

Between 2021 and 2025, the market experienced rapid growth from a relatively small base, primarily driven by new product approvals, accelerated clinical translation, and the low-base effect. Growth rates are expected to moderate during 2025 – 2030 and 2030 – 2035, while the overall market continues to expand, reflecting a gradual transition from early-stage market expansion toward more stable growth.

By 2035, the global market is projected to reach USD 32.0 billion, while China’s gene therapy therapeutics market is expected to reach RMB 22.8 billion.

China’s gene therapy therapeutics market is characterized by an early regulatory breakthrough, delayed commercialization growth, and substantial future growth potential. In 2003, Shenzhen SiBiono’s recombinant adenovirus-p53 injection, Gendicine®, received regulatory approval, marking an early milestone in gene therapy product approval and clinical translation in China.

As gene delivery vectors, manufacturing processes, clinical research capabilities, and regulatory review mechanisms continue to mature, alongside growing unmet medical needs in oncology, rare diseases, and inherited disorders, China’s gene therapy market is expected to enter a period of accelerated growth. Future product approvals, expanded clinical applications, improved reimbursement systems, and stronger value chain capabilities will collectively support further market expansion.

Looking ahead, gene therapy commercialization is expected to follow a development pathway characterized by initial breakthroughs in diseases with high treatment burdens, improved clinical translation through well-defined targets and measurable endpoints, and gradual penetration into chronic disease markets.

Ophthalmic diseases, hematologic disorders, and certain rare inherited diseases are expected to establish reimbursement pathways first. Oncology, CNS disorders, cardiovascular diseases, and metabolic conditions may subsequently unlock broader market opportunities as evidence of long-term efficacy, safety, and cost-effectiveness continues to accumulate.

4. Industry Ecosystem: Regulatory, Technological, and Quality Advances Accelerate the Scaling of Gene Therapy

The gene therapy industry is evolving from individual product breakthroughs toward a more mature ecosystem driven by coordinated advances in regulatory policies, technological innovation, and quality management systems.

On the regulatory front, global and Chinese regulatory frameworks continue to evolve, with increasingly clear technical guidelines and expedited approval pathways covering pharmaceutical development, nonclinical research, clinical development, long-term follow-up, and rare disease therapies. These developments are expected to reduce uncertainty in R&D and regulatory registration, facilitating the clinical translation of gene therapy products.

Meanwhile, technological advances in AI-assisted AAV vector design, base editing, RNA editing, and novel delivery systems are improving delivery efficiency, tissue targeting, editing precision, and in vivo safety. These innovations are supporting the expansion of gene therapy from early clinical proof of concept to applications across a broader range of diseases.

At the same time, as gene therapy products advance into late-stage clinical development and commercialization, regulatory requirements relating to CMC, potency testing, impurity control, stability studies, immunogenicity assessment, and long-term follow-up continue to increase. More rigorous and implementable quality control standards will facilitate the industry’s transition from early-stage innovation toward standardized, verifiable, and scalable manufacturing.

Against this backdrop, R&D investment, capital market financing, pharmaceutical mergers and acquisitions, and cross-border business development (BD) partnerships remain active across the global gene therapy industry. Companies are increasingly focusing on platform technology development, indication portfolio expansion, and multi-pipeline development strategies.

Chinese gene therapy companies are also progressing beyond domestic R&D and clinical translation toward international licensing, cross-border collaborative development, multinational clinical trials, and overseas regulatory submissions.

Currently, gene therapy remains primarily concentrated in areas with relatively well-defined disease mechanisms, including rare inherited disorders, ophthalmic diseases, and inherited hematologic conditions. However, continued advances in delivery technologies, manufacturing processes, and gene-editing tools are gradually extending its therapeutic scope toward more prevalent diseases, such as diabetes.

Looking ahead, companies with differentiated technology platforms, reliable manufacturing capabilities, global clinical development expertise, and diversified commercialization strategies will be better positioned to establish sustainable competitive advantages in the global gene therapy industry.

Key Topics Covered

– Overview of gene therapy: Definitions, classifications, core therapeutic strategies, and the evolution of the gene therapy industry in global and Chinese markets.

– Gene therapy industry chain and key technologies: Upstream and downstream value chains, viral vector manufacturing platforms, key bottlenecks in upstream and downstream processes, and potential areas for technological optimization.

– Commercialization prospects and value realization pathways: Clinical progress across major therapeutic indications, commercialization challenges, reimbursement models, and pathways for realizing the commercial value of gene therapies.

– Global and Chinese industry drivers and future development trends: Regulatory policies, capital investment, industry ecosystem development, and the evolving competitive landscape.

– Representative gene therapy company profiles: Development histories, R&D pipeline portfolios, and core industrialization capabilities of representative gene therapy developers in global and Chinese markets.

From technological breakthroughs to scalable manufacturing, and from clinical value to commercial realization, the global gene therapy industry is undergoing a critical transition from technology-driven development toward a model supported by the integration of technological innovation, industrialization, and commercialization. Looking ahead, companies with advanced technology platforms, scalable manufacturing capabilities, efficient clinical translation, and strong commercialization capabilities are expected to establish greater competitive advantages in the next phase of industry development.

Through the 2026 Global Gene Therapy Industry Development Blue Book, Frost & Sullivan aims to provide a comprehensive overview of the global and Chinese gene therapy industry, offering systematic market insights and strategic references for industry participants while supporting the industry’s progression toward greater maturity, standardization, and scalability.

About Frost & Sullivan’s Life Sciences Practice

The Life Sciences Practice of Frost & Sullivan has professional analytical capabilities and extensive project experience in the field of life sciences. Leveraging Frost & Sullivan’s global think tank resources and the cross-industry business development platform in Greater China, the Life Sciences Practice of Frost & Sullivan has unique core advantages in investment and financing services for the life sciences industry. The Life Sciences Practice of Frost & Sullivan has a wide range of corporate clients in China and has established a vast client network over the past 20 years, accumulating extensive project experience in various sub-sectors of life sciences.

Project types include Knowledge Center projects (in-depth content, promotional activities), Pre-IPO projects (DCF valuation, business plan services), IPO listing projects (industry consulting, clinical audit, fundraising and investment writing), market research, market value management, and strategic consulting. We also cooperate with well-known domestic and international information platforms and investment and financing institutions to provide one-stop solutions for enterprises in specialized sub-fields such as pharmaceuticals and medical devices, attracting widespread attention from investors.

Editorial Team

Yiwen Ding

Frost & Sullivan Greater China Life Sciences Consulting Manager

Email: [email protected]

Media Contact
Company Name: Frost & Sullivan
Contact Person: PR & Marketing
Email: Send Email
City: Shanghai
Country: China
Website: http://www.frostchina.com